These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26267383)

  • 1. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists.
    Nagahara T; Saitoh T; Kutsumura N; Irukayama-Tomobe Y; Ogawa Y; Kuroda D; Gouda H; Kumagai H; Fujii H; Yanagisawa M; Nagase H
    J Med Chem; 2015 Oct; 58(20):7931-7. PubMed ID: 26267383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
    Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
    Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Synthesis of Orexin 1 Receptor-Selective Agonists.
    Iio K; Hashimoto K; Nagumo Y; Amezawa M; Hasegawa T; Yamamoto N; Kutsumura N; Takeuchi K; Ishikawa Y; Yamamoto H; Tokuda A; Sato T; Uchida Y; Inoue A; Tanimura R; Yanagisawa M; Nagase H; Saitoh T
    J Med Chem; 2023 Apr; 66(8):5453-5464. PubMed ID: 37043436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.
    Zhang D; Perrey DA; Decker AM; Langston TL; Mavanji V; Harris DL; Kotz CM; Zhang Y
    J Med Chem; 2021 Jun; 64(12):8806-8825. PubMed ID: 34101446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
    Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
    J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
    Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
    Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
    Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
    PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the First Selective, Nonpeptidic Orexin 2 Receptor Agonists.
    Heifetz A; Bodkin MJ; Biggin PC
    J Med Chem; 2015 Oct; 58(20):7928-30. PubMed ID: 26375584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of a Therapeutic Drug for Narcolepsy].
    Irukayama-Tomobe Y; Yanagisawa M
    Brain Nerve; 2018 Nov; 70(11):1255-1263. PubMed ID: 30416119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26.
    Rinne MK; Leino TO; Turku A; Turunen PM; Steynen Y; Xhaard H; Wallén EAA; Kukkonen JP
    Eur J Pharmacol; 2018 Oct; 837():137-144. PubMed ID: 30194937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The present and future of synthetic orexin receptor agonists.
    Saitoh T; Sakurai T
    Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton.
    Hino T; Saitoh T; Nagumo Y; Yamamoto N; Kutsumura N; Irukayama-Tomobe Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2022 Mar; 59():128530. PubMed ID: 35007725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of New Orexin 2 Receptor Modulators Using
    Janockova J; Dolezal R; Nepovimova E; Kobrlova T; Benkova M; Kuca K; Konecny J; Mezeiova E; Melikova M; Hepnarova V; Ring A; Soukup O; Korabecny J
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: Switching of receptor selectivity by chirality on the tetralin ring.
    Iio K; Saitoh T; Ohshita R; Hino T; Amezawa M; Takayama Y; Nagumo Y; Yamamoto N; Kutsumura N; Irukayama-Tomobe Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
    Bioorg Med Chem Lett; 2022 Mar; 60():128555. PubMed ID: 35051577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice.
    Kaushik MK; Aritake K; Cherasse Y; Imanishi A; Kanbayashi T; Urade Y; Yanagisawa M
    Sleep; 2021 Aug; 44(8):. PubMed ID: 33609365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model.
    Ishikawa T; Hara H; Kawano A; Kimura H
    Pharmacol Biochem Behav; 2022 Oct; 220():173464. PubMed ID: 36108771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients.
    Evans R; Kimura H; Alexander R; Davies CH; Faessel H; Hartman DS; Ishikawa T; Ratti E; Shimizu K; Suzuki M; Tanaka S; Yukitake H; Dauvilliers Y; Mignot E
    Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2207531119. PubMed ID: 35994639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement of intact disulfide bonds in orexin-A-induced stimulation of gastric acid secretion that is mediated by OX1 receptor activation.
    Okumura T; Takeuchi S; Motomura W; Yamada H; Egashira Si S; Asahi S; Kanatani A; Ihara M; Kohgo Y
    Biochem Biophys Res Commun; 2001 Feb; 280(4):976-81. PubMed ID: 11162621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys.
    Yamada R; Narita N; Ishikawa T; Kakehi M; Kimura H
    Pharmacol Biochem Behav; 2024 Jan; 234():173690. PubMed ID: 38061670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.